GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of SURPASS — 15 things I got wrong before I got it right — 44 comments in the full submission. View in context.
3.7k
c/trialwatch·submitted 1 year ago by u/cloudy_vial_carol

SURPASS — 15 things I got wrong before I got it right

Paperbranch of 6 comments

The title is the argument: SURPASS — 15 things I got wrong before I got it right. Here is the rest of it. Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one. The registered protocol is public. Comparing…

Read the full submission and all 44 comments →

This branch

6 comments, started 1 year ago
u/hub_opssite staff199 points·1 year ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

replysharereportpermalink
u/cloudy_vial_carolOP131 points·1 year ago·edited

check who the comparator was before you compare anything

replysharereportpermalink
u/emil_agyeman147 points·1 year ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/yara_bakken96 points·1 year ago·edited

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/cloudy_vial_carolOP54 points·1 year ago

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/formulary_fighterappeals0 points·1 year ago

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →